This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignees: University of Illinois, Northwestern University. Active years: 2013-2018.
Company Filing History:
3 out of 2,421 
2 out of 2,213 
Years Active: 2013-2018
Title: Scott Thomas Brady: Innovator in Tauopathy Research
Introduction
Scott Thomas Brady is a notable inventor based in Chicago, IL (US). He has made significant contributions to the field of tauopathy research, holding a total of 3 patents. His work focuses on the prevention and treatment of tauopathies, which are neurodegenerative diseases associated with tau protein abnormalities.
Latest Patents
Brady's latest patents include innovative compositions and methods aimed at addressing tauopathies. One of his patents is titled "Composition and method for preventing or treating a tauopathy." This invention involves a composition that includes N-terminal amino acid residues of the tau protein, which play a crucial role in the toxic activation of a PP1/GSK3 signaling cascade and the inhibition of fast axonal transport in human tauopathies. Another patent, "Composition and method for treating a tauopathy," shares similar objectives and methodologies, further emphasizing his commitment to advancing treatment options for these complex conditions.
Career Highlights
Throughout his career, Scott Thomas Brady has worked with prestigious institutions such as the University of Illinois and Northwestern University. His research has significantly impacted the understanding and treatment of tauopathies, showcasing his dedication to scientific advancement.
Collaborations
Brady has collaborated with esteemed colleagues, including Gerardo Andres Morfini and Lester I. Binder. These partnerships have enriched his research and contributed to the development of innovative solutions in the field.
Conclusion
Scott Thomas Brady is a prominent figure in tauopathy research, with a focus on developing effective treatments through his patented innovations. His work continues to inspire advancements in the understanding of neurodegenerative diseases.